Mahurin Honors College Capstone Experience/Thesis Projects



Document Type



With the invention of advanced technology, focus has been put on understanding and looking for potential cures for many diseases, one of which is cancer. The difference in the leaving and non-leaving ligands of the FDA approved cancer drugs contributes to the differential cell specific cytotoxic effects. These drugs such as oxaliplatin approved for colorectal cancer, cisplatin approved for testicular cancer, and their analogs were used to treat different cancer cell lines in an MTT assay. This project aims to determine how changing the molecular shape of these compounds affects their uptake and toxicity into different cell lines. The assay used the metabolism of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliuM bromide to its insoluble purple colored formazan. The cytotoxicity of these compounds are measured using the absorbance which decreases with increasing drug concentration to calculate the IC50. This value gives the concentration of compound that inhibits mitochondrial reductase by 50%. The cell lines used in these experiments are the NTERA-2 cells, most notably the prostate cancer cell lines with the 293 Human Embryonic Kidney (HEK), a noncancerous line, cells as the control. The IC50 for the compound Pt (S, S-dach) (ox) was 20 μm. There was no significant increase in its effect on the NTERA-2 cells when the concentration was higher while the compound Pt(Me2dach) (ox) did not inhibit up to 50% cell survival in the NTERA-2 cells even at a concentration was 100 μm. Pt(en)𝐶𝑙2 did not give an IC50 value in the HEK cells (control cells). For the experiments on NTERA-2 cancer cells, Pt-(S, S-dach) (ox) was more effective and cytotoxic than Pt(Me2dach) (ox).

Advisor(s) or Committee Chair

Dr. Blairanne Williams


Chemical and Pharmacologic Phenomena | Medicinal-Pharmaceutical Chemistry | Oncology